top of page

JM-010 : Candidate for dyskinesia in Parkinson’s disease

  • Parkinson’s disease patients generally need to take L-dopa(Levodopa) for a long time to ameliorate symptoms of the disease. About 90% of patients who have been taking L-dopa(Levodopa) for 10 years or longer develop dyskinesia in Parkinson’s disease, a kind of movement disorder. However there is no appropriate drug to treat this condition.

  • Bukwang Pharmaceutical strategically acquired 100% shares of Contera Pharma, a CNS-focused Danish bioventure company based in Copenhagen, to develop JM-010, an innovative treatment of dyskinesia in Parkinson's disease patients.

  • Following completion of clinical Proof of Concept Study and Phase I PK Study in South Africa and Germany, respectively. Late Phase II Study in both United States and E.U. including Germany, France, Spain, Italy, Republic of Korea is currently undergoing.

  • In 2017, ‘JM-010’ received orphan drug designation from Korea Ministry of Food and Drug Safety.

  • JM-010 is an innovative drug that holds a novel mechanism of action as fixed dose combination of two safe marketed products in a proprietary formulation and acts on dyskinesia in Parkinson's disease by inhibiting neurotransmitters in pre-synaptic neurons.

JM-010 : 파킨슨병 환자의 레보도파 유도 운동장애 치료제
|    ​Korean    |
bottom of page